Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00336895 · ClinicalTrials.gov registry record · NA
Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients
A NA study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- NA
- Development phase
- 29
- Enrollment target
NCT00336895 is a NA study that has completed, run by University of Pittsburgh. The registered enrollment target is 29 participants.
The verdict
NCT00336895, a NA study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
Study Summary
The objective of this study is to determine the tolerability and safety of Myfortic in liver transplant patients. Patients receiving CellCept who have GI side effects will have CellCept discontinued and changed to Myfortic (Myfortic is a new drug similar to CellCept, except it is enteric-coated). Our hypothesis is that Myfortic has less GI side effects and will, therefore, be tolerated better than CellCept and also that Myfortic will have a comparable effectiveness to CellCept.
Interventions
- DRUG Myfortic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00336895
The ClinicalTrials.gov registry entry for NCT00336895 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Myfortic is the first listed.
NCT00336895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00336895 about?
NCT00336895 is a clinical study titled "Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients". The objective of this study is to determine the tolerability and safety of Myfortic in liver transplant patients. Patients receiving CellCept who have GI side effects will have CellCept discontinued and changed to Myfortic (Myfortic is a new drug similar to CellCept, except it is enteric-coated). Ou...
What is the current status of trial NCT00336895?
This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2006-11. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00336895?
The interventions under investigation include: Myfortic (DRUG).
Who is sponsoring clinical trial NCT00336895?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.